S&P 500   4,133.53 (-0.73%)
DOW   34,072.88 (-0.25%)
QQQ   304.58 (-1.71%)
AAPL   151.32 (-2.15%)
MSFT   268.74 (+0.44%)
META   185.16 (-3.37%)
GOOGL   99.08 (-7.95%)
AMZN   99.85 (-2.21%)
TSLA   198.62 (+0.92%)
NVDA   224.16 (+1.10%)
NIO   10.65 (-2.47%)
BABA   105.52 (+0.02%)
AMD   85.47 (-0.51%)
T   19.13 (-0.62%)
F   13.47 (+0.15%)
MU   60.60 (-2.46%)
CGC   2.76 (-2.13%)
GE   82.00 (-0.13%)
DIS   111.29 (-0.30%)
AMC   5.73 (-7.28%)
PFE   43.88 (+0.67%)
PYPL   80.16 (-3.69%)
NFLX   360.86 (-0.58%)
S&P 500   4,133.53 (-0.73%)
DOW   34,072.88 (-0.25%)
QQQ   304.58 (-1.71%)
AAPL   151.32 (-2.15%)
MSFT   268.74 (+0.44%)
META   185.16 (-3.37%)
GOOGL   99.08 (-7.95%)
AMZN   99.85 (-2.21%)
TSLA   198.62 (+0.92%)
NVDA   224.16 (+1.10%)
NIO   10.65 (-2.47%)
BABA   105.52 (+0.02%)
AMD   85.47 (-0.51%)
T   19.13 (-0.62%)
F   13.47 (+0.15%)
MU   60.60 (-2.46%)
CGC   2.76 (-2.13%)
GE   82.00 (-0.13%)
DIS   111.29 (-0.30%)
AMC   5.73 (-7.28%)
PFE   43.88 (+0.67%)
PYPL   80.16 (-3.69%)
NFLX   360.86 (-0.58%)
S&P 500   4,133.53 (-0.73%)
DOW   34,072.88 (-0.25%)
QQQ   304.58 (-1.71%)
AAPL   151.32 (-2.15%)
MSFT   268.74 (+0.44%)
META   185.16 (-3.37%)
GOOGL   99.08 (-7.95%)
AMZN   99.85 (-2.21%)
TSLA   198.62 (+0.92%)
NVDA   224.16 (+1.10%)
NIO   10.65 (-2.47%)
BABA   105.52 (+0.02%)
AMD   85.47 (-0.51%)
T   19.13 (-0.62%)
F   13.47 (+0.15%)
MU   60.60 (-2.46%)
CGC   2.76 (-2.13%)
GE   82.00 (-0.13%)
DIS   111.29 (-0.30%)
AMC   5.73 (-7.28%)
PFE   43.88 (+0.67%)
PYPL   80.16 (-3.69%)
NFLX   360.86 (-0.58%)
S&P 500   4,133.53 (-0.73%)
DOW   34,072.88 (-0.25%)
QQQ   304.58 (-1.71%)
AAPL   151.32 (-2.15%)
MSFT   268.74 (+0.44%)
META   185.16 (-3.37%)
GOOGL   99.08 (-7.95%)
AMZN   99.85 (-2.21%)
TSLA   198.62 (+0.92%)
NVDA   224.16 (+1.10%)
NIO   10.65 (-2.47%)
BABA   105.52 (+0.02%)
AMD   85.47 (-0.51%)
T   19.13 (-0.62%)
F   13.47 (+0.15%)
MU   60.60 (-2.46%)
CGC   2.76 (-2.13%)
GE   82.00 (-0.13%)
DIS   111.29 (-0.30%)
AMC   5.73 (-7.28%)
PFE   43.88 (+0.67%)
PYPL   80.16 (-3.69%)
NFLX   360.86 (-0.58%)
TSE:VBV

VBI Vaccines - VBV Stock Forecast, Price & News

Add
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1,300 shs
Average Volume
3,637 shs
Market Capitalization
C$308.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VBV stock logo

About VBI Vaccines (TSE:VBV) Stock

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Receive VBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBV Stock News Headlines

January 26, 2023 | foxnews.com
Yearly COVID vaccine as proposed by FDA? 'Cart before the horse,' says doctor
January 25, 2023 | abcnews.go.com
FDA proposes most Americans receive one annual COVID vaccine, similar to flu
February 8, 2023 | Investing Trends (Ad)
The Humble Mineral at the Heart of the EV Revolution (Not Lithium)
You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!
January 25, 2023 | reuters.com
U.S. FDA proposes shift to annual COVID vaccine shots
January 24, 2023 | cnet.com
Scientists Are Working on a COVID Vaccine You Can Drink
January 22, 2023 | cnbc.com
RSV vaccine: Moderna, Pfizer start a new FDA approval race
January 16, 2023 | nypost.com
CDC investigating whether Pfizer COVID vaccine increases stroke risk for people over 65
January 14, 2023 | marketwatch.com
Vaccine Market Latest Trends 2023, Drivers, and Projections Report from 2023-2029| 101 Pages Report
February 8, 2023 | Investing Trends (Ad)
The Humble Mineral at the Heart of the EV Revolution (Not Lithium)
You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!
January 14, 2023 | nypost.com
Moderna under fire for 400% price hike of COVID vaccine: ‘Outrageous’
January 13, 2023 | nypost.com
Pentagon ends COVID-19 vaccine mandate for US troops
January 10, 2023 | marketwatch.com
VLP Vaccines Market Global and Regional Analysis and Forecast 2028
December 20, 2022 | msn.com
Looking Into VBI Vaccines's Return On Capital Employed
November 10, 2022 | marketwatch.com
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 15, 2022 | finance.yahoo.com
FDA Approves Vaccine for Use During Third Trimester of Pregnancy to Prevent Whooping Cough in Infants Younger Than Two Months of Age
September 15, 2022 | finance.yahoo.com
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
September 8, 2022 | barrons.com
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri(R)
September 8, 2022 | tmcnet.com
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
August 8, 2022 | seekingalpha.com
VBI Vaccines stock slumps 10% on Q2 miss, net loss widens on forex impact
June 22, 2022 | seekingalpha.com
VBI Vaccines gets FDA orphan drug designation for brain cancer vaccine candidate VBI-1901
June 1, 2022 | seekingalpha.com
VBI Vaccines hepatitis B shot PreHevbri gets approval in UK
October 26, 2021 | finance.yahoo.com
VBI Vaccines Inc. (VBV.TO)
February 16, 2021 | theglobeandmail.com
One shot to protect us all: Canadian scientists’ quest to develop a vaccine that fights all types of coronavirus
February 2, 2021 | marketwatch.com
Cancer Vaccines Market Growing At A CAGR Of 12.6% And To Target $7.30 Billion By 2027
January 22, 2021 | nasdaq.com
VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine
January 17, 2021 | seekingalpha.com
VBI's 3-antigen HBV vaccine demonstrates robust immunogenicity, shares up 9%
November 23, 2020 | businesswire.com
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency
See More Headlines
Receive VBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
N/A
Sub-Industry
N/A
Sector
N/A
Current Symbol
TSE:VBV
CUSIP
N/A
CIK
N/A
Web
www.vbivaccines.com
Phone
+1-617-8303031
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
14.29
Current Ratio
2.64
Quick Ratio
2.54

Sales & Book Value

Annual Sales
C$3.36 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
C$1.01 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
64,079,000
Free Float
N/A
Market Cap
C$308.86 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Jeff R. Baxter (Age 57)
    CEO, Pres & Director
  • Dr. David Evander Anderson Ph.D. (Age 48)
    Chief Scientific Officer
  • Ms. Athena Kartsaklis (Age 53)
    Sr. VP of Fin., Principal Financial & Accounting Officer, Chief Compliance Officer
  • Ms. Nell Beattie (Age 30)
    Chief Bus. Officer
  • Dr. Francisco Diaz-Mitoma M.D. (Age 63)
    Ph.D., Chief Medical Officer













VBV Stock - Frequently Asked Questions

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Teladoc Health (TDOC), PhaseBio Pharmaceuticals (PHAS), Amarin (AMRN), Adverum Biotechnologies (ADVM), Assertio (ASRT), Activision Blizzard (ATVI), Axsome Therapeutics (AXSM), Boeing (BA), Beyond Meat (BYND) and Cardlytics (CDLX).

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VBV."

How do I buy shares of VBI Vaccines?

Shares of VBV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does VBI Vaccines make?

VBI Vaccines (TSE:VBV) has a market capitalization of C$0.00 and generates C$3.36 million in revenue each year.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 3rd St Ste 2241, CAMBRIDGE, MA 02142-1259, United States. The official website for the company is www.vbivaccines.com. The company can be reached via phone at +1-617-8303031.

This page (TSE:VBV) was last updated on 2/8/2023 by MarketBeat.com Staff